HCV | WEBCASTS

Beginning Date

12/31/2014

Ending Date

12/31/2015

3.5

credits

3.5

contact hours

Speakers

Steven Flamm, MD
Feinberg School of Medicine
Northwestern University
Chicago, IL

Paul Kwo, MD
Indiana University Medical Center
Indianapolis, IN

Bruce Levy, MD, JD
C.E.O. Austin Gastroenterology and Austin Endoscopy Centers
Austin, TX

Webcasts

All webcasts must be viewed in their entirety to claim credit.

Cirrhosis: Diagnosing, Staging, Prognosis and Managing Complications

Hepatocellular Carcinoma: Risk Factors, Prevention, Surveillance and Treatment

Non-alcoholic Fatty Liver Disease: Prevalence, Progression and Review of Latest

HCV: Screening, Diagnosis and Treatment Update

Healthcare Reform: Quality Measures and the Impact on Practices

Certified by:

This activity is endorsed by the International Coalition of Hepatology Educational Providers and provided by the Chronic Liver Disease Foundation.

This activity Supported by:

AbbVie, Bayer Health Care Pharmaceuticals, Bristol-Myers Squibb, Janssen Therapeutics and Onyx Pharmaceuticals.

Target Audience

This activity has been designed to meet the educational needs of hepatologists, primary care providers, nurse practitioners/physician assistants, allied health care professionals, clinical pharmacists, and managed care decision makers.

Educational Objectives

At the conclusion of this activity, participants will be able to:

•	Identify the risk factors and symptoms of chronic liver disease
•	Discuss laboratory tests and invasive/noninvasive methodologies used to ascertain the underlying cause and classify the stage of disease
•	Describe screening and treatment for patients with cirrhosis/hepatocellular carcinoma
•	Apply the AASLD guidelines on screening, diagnosis, and treatment of patients infected with chronic hepatitis C
•	Recognize the safety and efficacy of currently available HCV therapies and those expected in the next 6 months and advise patients regarding treatment options based on their individual characteristics

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Annenberg Center for Health Sciences at Eisenhower, the Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-Hep). The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this online activity for a maximum of 3.5 AMA PRA Category 1 Credit(s)^™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program has been developed according to the ACPE Criteria for Quality and is assigned ACPE Universal Program #0797-9999-14-126-L04-P. This program is designated for up to 3.5 contact hours (0.35 CEUs) of continuing pharmacy education credit.

Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

A maximum of 3.5 contact hours may be earned for successful completion of this activity. Provider is approved by the California Board of Registered Nursing, Provider # 13664, for 3.5 contact hours.

Disclosure of Conflicts of Interest:

All faculty and staff involved in the planning or presentation of continuing education activities sponsored/provided by Annenberg Center for Health Sciences at Eisenhower (ACHS) are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. Charles Willis, Director of Continuing Education, consults for Pfizer, Inc.; John Bayliss, VP, Business Development, partner is an employee of Amgen, Inc.; all other staff at the Annenberg Center for Health Sciences at Eisenhower and the Chronic Liver Disease Foundation have no relevant commercial relationships to disclose.

Learner Assurance Statement:

The Annenberg Center for Health Sciences at Eisenhower is committed to resolving all conflicts of interest issues that could arise as a result of prospective faculty members' significant relationships with drug or device manufacturer(s). The Annenberg Center for Health Sciences at Eisenhower is committed to retaining only those speakers with financial interests that can be reconciled with the goals and educational integrity of the CME activity.

This is an invitation only. Submission of this form does not guarantee a seat at this meeting. Registration is confirmed on a first-come-first-served basis. Once your registration is processed, you will be notified regarding availability for this meeting.

Faculty Disclosures:

Steven Flamm, MD has received Grants/Research Support from Bristol-Myers Squibb, Gilead Sciences, AbbVie, Salix, and Janssen. He is a Consultant or Speaker Bureau Member for Gilead Sciences, AbbVie, Salix, and Janssen. He is an Advisory Board Member for Bristol-Myers Squibb, Gilead, AbbVie, Salix, and Janssen.

Paul Kwo, MD has received Grants/Research Support from Merck, AbbVie, Bristol-Myers Squibb, Gilead Science, La Jolla Pharmaceuticals, Janssen, Conatus, Roche. He is an Advisory Board Member for Merck, AbbVie, Bristol-Myers Squibb, Gilead Sciences and Janssen.

Bruce Levy, MD, JD has no relationships to disclose at this time.